Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,827,168 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,827,168 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,825,740 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,825,740 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,849,737 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,849,737 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,859,453 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,859,453 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,842,366 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,842,366 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,428 | $92.37 | $131,904.36 |
DisclosureSEC source: 0001753159-26-000008 · wk-form4_1775164793.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,129,878 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000008 · wk-form4_1775164793.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,131,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 101,409 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · derivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,409 Underlying: Common Stock · 101,409 shares Expires not disclosed F6 · derivative.exercise_date: This represents a restricted stock unit award granted on March 17, 2026 that vests over a three-year period. 33% of the shares subject to such award vests on January 1, 2027 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F4 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 11,268 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · derivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,268 Underlying: Common Stock · 11,268 shares Expires not disclosed F5 · derivative.exercise_date: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F4 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 26,961 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · derivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,961 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 13,664 | $85.49 | $1,168,135.36 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,128,489 F2 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 26,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,142,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 23,997 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000002 · wk-form4_1767653791.xml · derivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,989 Underlying: Common Stock · 23,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 10,788 | $102.14 | $1,101,886.32 |
DisclosureSEC source: 0001753159-26-000002 · wk-form4_1767653791.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,013,457 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 23,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000002 · wk-form4_1767653791.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,024,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 38,283 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · derivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,727 Underlying: Common Stock · 38,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vested with respect to 33% of the shares on January 1, 2026 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F4 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 19,402 | $102.14 | $1,981,720.28 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,115,192 F2 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| January 01, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 38,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,134,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 13,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,096,311 F1 · shares: Reflects changes in form of ownership from direct to indirect due to transfer of shares to Talasaz and Eskandari 2017 Family Trust. Read SEC document |
| January 01, 2026 Filed Mar 18, 2026 01:57 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 13,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000006 · wk-form4_1773799065.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Reflects changes in form of ownership from direct to indirect due to transfer of shares to Talasaz and Eskandari 2017 Family Trust. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 4,815 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000002 · wk-form4_1767653791.xml · derivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,815 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests in four equal installments on the last day of each calendar quarter, March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 2,441 | $102.14 | $249,323.74 |
DisclosureSEC source: 0001753159-26-000002 · wk-form4_1767653791.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,248 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 4,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000002 · wk-form4_1767653791.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,002,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2025 Filed Jan 22, 2026 22:44 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 82,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000004 · wk-form5_1769121839.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,083,102 F2 · shares: Reflects changes in form of ownership from Talasaz Investments LP due to the transfer of shares to Talasaz and Eskandari 2017 Family Trust. Read SEC document |
| December 31, 2025 Filed Jan 22, 2026 22:44 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 2,000,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000004 · wk-form5_1769121839.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 2,000,248 F1 · shares: Reflects changes in form of ownership from direct to indirect due to transfer of shares to Talasaz and Eskandari 2017 Family Trust. Read SEC document |
| December 31, 2025 Filed Jan 22, 2026 22:44 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 82,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000004 · wk-form5_1769121839.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 0 F2 · shares: Reflects changes in form of ownership from Talasaz Investments LP due to the transfer of shares to Talasaz and Eskandari 2017 Family Trust. Read SEC document |
| December 31, 2025 Filed Jan 22, 2026 22:44 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 2,000,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-26-000004 · wk-form5_1769121839.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,209 F1 · shares: Reflects changes in form of ownership from direct to indirect due to transfer of shares to Talasaz and Eskandari 2017 Family Trust. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 4,240 | $106.00 | $449,440.00 |
DisclosureSEC source: 0001753159-25-000006 · wk-form4_1765420401.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 168,223 Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 30,760 | $105.34 | $3,240,172.27 |
DisclosureSEC source: 0001753159-25-000006 · wk-form4_1765420401.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 172,463 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.81. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 15,000 | $104.21 | $1,563,124.50 |
DisclosureSEC source: 0001753159-25-000006 · wk-form4_1765420401.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 203,223 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.00 to $104.75. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 4,240 | $106.00 | $449,440.00 |
DisclosureSEC source: 0001753159-25-000006 · wk-form4_1765420401.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 168,223 Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 30,760 | $105.34 | $3,240,172.27 |
DisclosureSEC source: 0001753159-25-000006 · wk-form4_1765420401.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 172,463 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.81. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 15,000 | $104.21 | $1,563,124.50 |
DisclosureSEC source: 0001753159-25-000006 · wk-form4_1765420401.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 203,223 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.00 to $104.75. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:33 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 193,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-25-000006 · wk-form4_1765420401.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Maryam Eskandari 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 218,223 Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:33 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 193,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-25-000006 · wk-form4_1765420401.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by AmirAli Talasaz 2018 Children's Remainder Trust, Dated 9/25/2018 Disclosed balance after: 218,223 F1 · shares: Reflects changes in form of ownership from Talasaz Investments LP due to the transfer of shares to The AmirAli Talasaz 2018 Children's Remainder Trust dated 9/25/2018, and Maryam Eskandari 2018 Children's Remainder Trust, dated 9/25/2018. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:33 UTC | Guardant Health, Inc. GH · Entity 3238 | OtherCommon Stock | 387,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-25-000006 · wk-form4_1765420401.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 82,854 F1 · shares: Reflects changes in form of ownership from Talasaz Investments LP due to the transfer of shares to The AmirAli Talasaz 2018 Children's Remainder Trust dated 9/25/2018, and Maryam Eskandari 2018 Children's Remainder Trust, dated 9/25/2018. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 23,997 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-25-000004 · wk-form4_1759449830.xml · derivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,986 Underlying: Common Stock · 23,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two year period. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 12,162 | $62.65 | $761,949.30 |
DisclosureSEC source: 0001753159-25-000004 · wk-form4_1759449830.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,997,874 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 23,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-25-000004 · wk-form4_1759449830.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,010,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2025 Filed Oct 3, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 4,814 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001753159-25-000004 · wk-form4_1759449830.xml · derivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,815 Underlying: Common Stock · 4,814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests in four equal installments on the last day of each calendar quarter, March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 30, 2025 Filed Oct 3, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 2,440 | $62.48 | $152,451.20 |
DisclosureSEC source: 0001753159-25-000004 · wk-form4_1759449830.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,986,039 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 30, 2025 Filed Oct 3, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 4,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001753159-25-000004 · wk-form4_1759449830.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,988,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:18 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 23,997 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000213 · wk-form4_1751505523.xml · derivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,983 Underlying: Common Stock · 23,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This restricted stock unit award vested with respect to 1/3 of the shares on January 1, 2025. The remaining shares vest quarterly for the remaining twenty-four months. F6 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:18 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 12,162 | $50.71 | $616,735.02 |
DisclosureSEC source: 0001576280-25-000213 · wk-form4_1751505523.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,983,665 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:18 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 23,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000213 · wk-form4_1751505523.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,995,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:18 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 27,932 | $51.40 | $1,435,836.08 |
DisclosureSEC source: 0001576280-25-000213 · wk-form4_1751505523.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,971,830 F2 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.08 to $51.94 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:18 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 72,068 | $50.67 | $3,651,793.66 |
DisclosureSEC source: 0001576280-25-000213 · wk-form4_1751505523.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,999,762 F2 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.08 to $51.07 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2025 Filed Jul 3, 2025 01:18 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 4,815 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000213 · wk-form4_1751505523.xml · derivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,629 Underlying: Common Stock · 4,815 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests in four equal installments on the last day of each calendar quarter, March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025. F6 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 30, 2025 Filed Jul 3, 2025 01:18 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 2,441 | $52.04 | $127,029.64 |
DisclosureSEC source: 0001576280-25-000213 · wk-form4_1751505523.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,071,830 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 30, 2025 Filed Jul 3, 2025 01:18 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 4,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000213 · wk-form4_1751505523.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,074,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 01:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 77,853 | $50.09 | $3,899,937.04 |
DisclosureSEC source: 0001576280-25-000169 · wk-form4_1749519929.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,069,456 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.41 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 01:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 39,751 | $50.07 | $1,990,420.02 |
DisclosureSEC source: 0001576280-25-000169 · wk-form4_1749519929.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,147,309 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 05, 2025 Filed Jun 10, 2025 01:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 1,680 | $50.00 | $84,006.89 |
DisclosureSEC source: 0001576280-25-000169 · wk-form4_1749519929.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,187,060 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.04 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 02, 2025 Filed May 6, 2025 01:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 13,932 | $50.47 | $703,150.83 |
DisclosureSEC source: 0001576280-25-000141 · wk-form4_1746493315.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,188,740 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.84 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 6, 2025 01:02 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 354 | $52.57 | $18,610.81 |
DisclosureSEC source: 0001576280-25-000141 · wk-form4_1746493315.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Co-Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,202,672 F1 · shares: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2024. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.46 to $52.75 per shares, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.